RHAPSIDO (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
RHAPSIDO
Date registered
Evaluation commenced
Decision date
Approval time
190 (255 working days)
Active ingredients
remibrutinib
Registration type
NCE/NBE
Indication
Chronic spontaneous urticaria (CSU)
RHAPSIDO is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment.